glp-1 and gip dual agonist GIPR/GLP-1R therapies for diabetes weight loss—chemistry, physiology, and clinical applications GLP-1 & GIP Agonists |
Description
The most significant is the restricted number of included studies
Other common structural changes include aortic stenosis, myocardial fibrosis and myocyte stiffness
Smith, G
Additionally, the higher risk of surgical and long-term complications necessitates careful patient selection
Glucagon-like peptide1 (GLP1): A gut hormone of potential interest in the treatment of diabetes
The baseline HbA1c in the tirzepatide arms was 7.85%7.97% and 8.05% in the study arm receiving a placebo
